Broadcom’s Vmware Draws More Regulatory Attention, This Time From EU

U.S. chipmaker Broadcom Inc’s (NASDAQ:AVGO) $61 billion Vmware, Inc (NYSE:VMW) deal could hit a roadblock with EU antitrust regulators poised to open…
  • U.S. chipmaker Broadcom Inc’s (NASDAQ:AVGO) $61 billion Vmware, Inc (NYSE:VMW) deal could hit a roadblock with EU antitrust regulators poised to open a full-scale investigation into the deal.
  • The proposed transaction reflected Broadcom’s attempt to diversify its business into enterprise software but coincided with regulators’ scrutiny of deals by Big Tech, Reuters reports.
  • Broadcom pined for early EU approval of the deal by highlighting competition from Amazon.com Inc (NASDAQ: AMZN), Microsoft Corp (NASDAQ: MSFT), and Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGLGoogle in the cloud computing market.
  • Broadcom had a so-called state-of-play meeting with European Commission officials earlier this week.
  • The EU competition enforcer will likely finish its initial deal scrutiny on December 20.
  • Broadcom expected the timeline for the review process to extend in other vital regions due to the deal size.
  • Beltug, a Belgian association of CIOs & Digital Technology leaders, and its counterparts France’s Cigref, CIO platform Nederland and VOICE Germany had voiced their fears over the deal leading to drastic price hikes and more brutal commercial practices against customers.
  • In November, the Competition and Markets Authority (CMA) invited comments to help it formally assess whether to launch an investigation into the Broadcom-VMware deal.
  • Price Action: AVGO shares closed higher by 2.57% at $544.72 on Friday.
Total
0
Shares
Related Posts
Read More

MaxCyte Signed Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Curamys, a South Korean biotechnology company that develops cell & gene therapy using cell fusion technology to treat

MXCT